Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 387-392

  Drescher, Charles W ^a   Shah, Chirag ^a   Thorpe, Jason ^a   O'Briant, Kathy ^a   Anderson, Garnet L ^a   Berg, Christine D ^b   Urban, Nicole ^a   McIntosh, Martin W ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ALGORITHM; ARTICLE; BAYES THEOREM; CANCER SCREENING; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY;

AGED; ALGORITHMS; CA-125 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LONGITUDINAL STUDIES; MEMBRANE PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84873389024     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.6691     Document Type: Article

References (22)

1. McIntosh MW, Urban N: A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 4:27-40, 2003 (Pubitemid 36116886)
2. McIntosh MW, Urban N, Karlan B: Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev 11:159-166, 2002 (Pubitemid 34202997)
3. Skates S, Pauler D, Jacobs I: Screening based on the risk of cancer calculation from Bayesian hierarchical change point and mixture models of longitudinal markers. J Amer Stat Assoc 96:429-439, 2001
4. Lin H, Turnbull B, Mcculloc CE, et al: Latent class models for joint analysis of longitudinal biomarker and event process data: application to longitudinal prostate-specific antigen readings and prostate cancer. J Amer Stat Assoc 97:53-65, 2002
5. Sato AH, Anderson GL, Urban N, et al: Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers. Cancer Biomark 2:151-162, 2006
6. Crump C, McIntosh MW, Urban N, et al: Ovarian cancer tumor marker behavior in asymptomatic healthy women: Implications for screening. Cancer Epidemiol Biomarkers Prev 9:1107-1111, 2000
7. Sottas PE, Baume N, Saudan C, et al: Bayesian detection of abnormal values in longitudinal biomarkers with an application to T/E ratio. Biostatistics 8:285-296, 2007 (Pubitemid 46569590)
8. Sottas PE, Saudan C, Schweizer C, et al: From population-to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci Int 174:166-172, 2008
9. Van Renterghem P, Van Eenoo P, Sottas PE, et al: A pilot study on subject-based comprehensive steroid profiling: Novel biomarkers to detect testosterone misuse in sports. Clin Endocrinol (Oxf) 10.1111/j.1365-2265.2011. 03992.x [epub ahead of print on February 2, 2011]
10. Sottas PE, Robinson N, Saugy M, Niggli O: A forensic approach to the interpretation of blood doping markers. Law, Probability and Risk 7:191-210, 2008
11. Gohagan J, Marcus P, Fagerstrom R, et al: Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: The Lung Screening Study of the National Cancer Institute. Chest 126:114-121, 2004 (Pubitemid 38943126)
12. Gohagan JK, Prorok PC, Hayes RB, et al: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status. Control Clin Trials 21:251S-272S, 2000 (6 suppl)
13. Buys SS, Partridge E, Black A, et al: Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305:2295-2303, 2011
14. Pauler DK, Menon U, McIntosh M, et al: Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 10:489-493, 2001 (Pubitemid 32701635)
15. Skates SJ, Xu FJ, Yu YH, et al: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76:2004-2010, 1995 (10 suppl)
16. Bliese PD: Within-group agreement, nonindependence, and reliability: Implications for data aggregation and analysis, in KJKSWK (ed): Multilevel Theory, Research, and Methods in Organizations. San Francisco, CA, Jossey-Bass, 2000, pp 349-381
17. Bliese P: Multilevel: Multilevel functions. R package 2.3 (ed 2008)
18. Team RDC. A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing, 2009
19. Zhu CS, Pinsky PF, Cramer DW, et al: A framework for evaluating biomarkers for early detection: Validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) 4:375-383, 2011
20. Urban N, Thorpe JD, Bergan LA, et al: Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst 103:1630-1634, 2011
21. Cramer DW, Bast RC Jr, Berg CD, et al: Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 4:365-374, 2011
22. Menon U, Skates SJ, Lewis S, et al: Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23:7919-7926, 2005 (Pubitemid 46657391)